Protox completes enrollment of Phase 2b BPH trial



    VANCOUVER, Sept. 8 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader
in the development of receptor targeted fusion proteins, today announced that
it has completed patient enrollment in its multi-centre, double-blinded,
placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males
with moderate to severe benign prostatic hyperplasia (BPH), a common and
bothersome urological condition that affects more than 50 million men
worldwide.
    "We look forward with great anticipation, the potential to report
top-line results from the TRIUMPH study before the end of 2009," said Dr Fahar
Merchant, President and CEO of Protox. "This is a significant milestone for
the company and we are delighted with the rapid enrollment as it underscores
the enthusiasm for PRX302 among the physician and patient communities."
    TRIUMPH is the third BPH clinical trial of PRX302 conducted by Protox. In
addition to being well-tolerated, the previous open-label Phase 2 study
reported at the 2009 Annual Meeting of the American Urological Association,
showed an 11 point improvement in the International Prostate Symptom Score at
the optimal PRX302 dose used in the TRIUMPH study.

    About TRIUMPH

    In this multi-centre, double-blinded placebo controlled Phase 2b study,
approximately 90 patients with moderate to severe BPH were randomized 2:1
(treatment : placebo). Each patient received PRX302 (3(micro)g/mL) or placebo
at a volume equivalent to 20 percent of the total prostate volume. Dosing for
each arm was delivered via a single ultrasound-guided injection into each lobe
of the prostate. The primary objective of this study is to evaluate the
efficacy of PRX302 compared to placebo as measured by the changes in IPSS
(International Prostate Symptom Score) in subjects with moderate to severe BPH
at 90 days post-treatment. In addition, the study will also compare efficacy
of PRX302 with respect to changes from baseline in Quality of Life scores
(QoL), urodynamic parameters (Qmax, PVR), proportion of responders and
prostate size.
    The co-principal investigators of this trial are Dr Mostafa M. Elhilali,
OC, M.D., Ph.D, Stephen Jarislowsky Chair in Urology at McGill University and
Dr. Peter Pommerville, M.D., Director of Research at Can-Med Clinical Research
Centre in Victoria, B.C. The study is being conducted at 9 sites across
Canada.

    About PRX302

    PRX302 is the lead drug in the company's PORxin(TM) technology platform.
PORxin drugs are pore-forming pro-drugs that are activated by specific
proteases produced at elevated levels on the surface of target cells. PRX302
has been generated by engineering the naturally occurring toxin proaerolysin
so that it is activated by prostate-specific antigen (PSA), an enzyme that is
overproduced in patients suffering from BPH and prostate cancer. Once
activated, the drug punches holes in the cells causing the contents to leak
out and ultimately cell death.

    About BPH

    BPH is a common urological condition characterized by painful and
bothersome symptoms that include difficulty in initiating a urine stream, a
sense of urgency, dribbling, incomplete emptying of the bladder, waking
several times during the night to urinate and sometimes the presence of blood
in the urine. More than half of all men will have symptoms of BPH by the age
of 60 and as many as 90% may suffer from BPH after the age of 80. Current oral
therapies mainly provide symptomatic relief, may take months before they take
effect and can trigger a range of side effects including sexual dysfunction
and hypotension. It is estimated that in the seven largest global markets
approximately 10 million men are treated annually with oral therapies and
these products encompass approximately U.S. $3 billion of sales each year.
Surgical options, including minimally invasive procedures, can cause sexual
dysfunction, incontinence as well as other more serious procedure-related
effects. Surgical measures can require significant recovery time and may
require catheterization for up to several weeks post-treatment. Nearly 600,000
surgical procedures are conducted annually in the seven largest markets.

    About Protox

    Protox Therapeutics is a leader in advancing novel, receptor targeted
fusion proteins. Two novel drug candidates derived from the company's
INxin(TM) and PORxin(TM) platforms are being developed in three clinical
programs. Protox's lead program, PRX302 (PORxin), is currently being studied
in a Phase 2b placebo controlled trial to treat benign prostatic hyperplasia
(BPH or enlarged prostate). Positive Phase 2a results treating BPH patients
were released at the end of 2008 and a phase 2a clinical trial evaluating
PRX302 for the treatment of localized prostate cancer is ongoing. A Phase 2a
clinical trial evaluating PRX321 (INxin) for the treatment of primary brain
cancer has been completed and the drug has received Fast Track Designation and
Orphan Drug Status from the US FDA and EMEA. Protox is also collaborating with
the U.S. National Institutes of Health (NIH) on a research program focused on
the discovery of next generation fully human targeted therapeutics.

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.





For further information:

For further information: James Beesley, Senior Director, Investor
Relations, Protox Therapeutics, (604) 484-0975,
jbeesley@protoxtherapeutics.com; Michael Moore, Investor Relations, Equicom
Group, (416) 815-0700 x 241, mmoore@equicomgroup.com

Organization Profile

Sophiris Bio, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890